CSPC Pharmaceutical Company Ltd. (CSPC), the parent company of Conjupro, is the 3rd largest pharmaceutical company in China, comprised of 15 subsidiary companies, 10 in China and 5 in the US, and over 24,000 employees. It has been listed on the Hong Kong Stock Exchange since 1994 (Stock code: 1093.HK).

Market Leaders

With its motto “All for good medicine, all for mankind’s health”, CSPC has been at the forefront of researching, manufacturing, and marketing medicines and other pharmaceutical products. CSPC focuses on improving consumer health through three major segments: OTC products, generic drugs, and bulk drugs. The Group has nearly 1,000 marketed drug products to date, including antibiotics, cardio-cerebrovascular drugs, antipyretic analgesic drugs, digestive system drugs, oncology drugs and traditional Chinese medicine. Of which, “NBP”, “Oulaining”, “Xuanning”. “Duomeisu”, “Jinyouli” and “Nuolining” are the bestselling innovative drugs products of the Group in China. Bulk drugs products include antibiotics, vitamin C and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. The brand has been listed as one of the “Top 500 Most Valuable Brands in China” by the World Brand Lab every year since 2004. With its 10,000 Sales Reps and 3-dimensional distribution network, CSPC occupies the largest commercial platform in China.

Rich Product Pipeline

The Group possesses strong R&D capabilities and a rich product pipeline. The Central Drug Research Institute, located at CSPC’s headquarters, is formed by a strong professional team of overseas returnees and staff with advanced degrees. Currently, the Group has over 300 projects in the pipeline including Class 1 and 3 new drugs or new preparations, with focus on five major therapeutic areas: cardio-cerebrovascular, metabolic diseases, oncology, psychiatry and neurology, as well as infectious disease. With regard to overseas registrations, “levamlodipine maleate tablets” was submitted for NDA to the U.S. FDA on 28Feb2019 and approved on 19Dec2019. In addition, several drugs have been granted the orphan drug designations in U.S.

Innovation-driven Strategy

CSPC implements the innovation-driven strategy by continuously investing in research and development and coping internal development with external cooperation to enhance the drive for innovation. This ensures that the performance of the Group will continue to grow and greater contributions could be made to the shareholders and the community.

Visit the CSPC website to learn more: https://www.e-cspc.com